The bill amends Chapter 42-56 of the General Laws to establish a program within adult correctional institutions for the treatment of opioid use disorder using FDA-approved medications. It defines "medication for opioid use disorder" and mandates that each inmate be screened for opioid use disorder within 24 hours of admission. Those diagnosed with opioid use disorder will be offered voluntary participation in the program, which will include individualized treatment plans and the provision of all forms of FDA-approved medications for the duration of their incarceration. Inmates currently on medication for opioid use disorder will be allowed to continue their treatment pending medical evaluation.

The bill ensures that no inmate will be denied participation in the program based on positive drug screenings or disciplinary infractions. It also includes a re-entry strategy for participants, providing them with information on available treatment facilities, housing, and employment resources to assist in their continued recovery post-release. The Department of Corrections is required to submit an annual report on the program's effectiveness, including an analysis of its impact on participants and institutional safety.

Furthermore, the bill clarifies that it will not interfere with existing laws governing opioid treatment and will respect the provider-patient relationship. The act is set to take effect on January 1, 2026.